Trevena Receives Milestone Payment From Partner in China Jiangsu Nhwa Pharmaceutical
Trevena Receives Milestone Payment From Partner in China Jiangsu Nhwa Pharmaceutical
Trevena 收到来自中国合作伙伴的里程碑式付款江苏恩华制药
Trevena, Inc. (NASDAQ:TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that it has received a $3 million milestone payment from its partner in China for the Chinese approval of OLINVYK. Jiangsu Nhwa Pharmaceutical Co. Ltd. (Nhwa) holds an exclusive license agreement to develop, manufacture, and commercialize OLINVYK in China.
Trevena, Inc.（纳斯达克股票代码：TRVN）， 一家专注于中枢神经系统（CNS）疾病患者新药开发和商业化的生物制药公司今天宣布，它已从中国合作伙伴那里获得300万美元的里程碑式付款，用于中国批准OLINVYK。江苏恩华药业有限公司Ltd.（Nhwa）持有在中国开发、制造和商业化OLINVYK的独家许可协议。